SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

PHIA

21.75

-1.27%↓

FME

37.23

+0.92%↑

SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

PHIA

21.75

-1.27%↓

FME

37.23

+0.92%↑

SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

PHIA

21.75

-1.27%↓

FME

37.23

+0.92%↑

SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

PHIA

21.75

-1.27%↓

FME

37.23

+0.92%↑

SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

PHIA

21.75

-1.27%↓

FME

37.23

+0.92%↑

Search

Fresenius SE & Co KGaA

Gesloten

SectorGezondheidszorg

38.8 -0.33

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

38.78

Max

39.48

Belangrijke statistieken

By Trading Economics

Inkomsten

31M

436M

Verkoop

-337M

5.8B

K/W

Sectorgemiddelde

14.881

51.415

EPS

0.99

Dividendrendement

2.56

Winstmarge

7.493

Werknemers

177,783

EBITDA

58M

902M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+43.39% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

2.56%

2.34%

Volgende Winsten

5 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

248M

22B

Vorige openingsprijs

39.13

Vorige sluitingsprijs

38.8

Nieuwssentiment

By Acuity

51%

49%

270 / 345 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

Fresenius SE & Co KGaA Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 aug 2025, 10:45 UTC

Marktinformatie
Winsten

Fresenius Beats Subdued Expectations -- Market Talk

Peer Vergelijking

Prijswijziging

Fresenius SE & Co KGaA Prognose

Koersdoel

By TipRanks

43.39% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 54.96 EUR  43.39%

Hoogste 58 EUR

Laagste 48 EUR

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Fresenius SE & Co KGaA - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

9

Buy

1

Hold

0

Sell

Technische score

By Trading Central

42.5 / 43.2Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Bullish Evidence

Sentiment

By Acuity

270 / 345 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Fresenius SE & Co KGaA

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
help-icon Live chat